Dr. Takeshima@Web

    Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, et al.  A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.  Expert Opinion on Drug Safety. 2022:1-8.  

 Sakai F, Hirata K, Igarashi H, Takeshima T, Nakayama T, Sano H, et al.  A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan.  J Headache Pain. 2022;23(1):70. https://www.ncbi.nlm.nih.gov/pubmed/35733104 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219245/pdf/10194_2022_Article_1439.pdf 2022/06/23